What is PE-22-28, and what is it studied for?
PE-22-28 is a seven-residue fragment of spadin, the sortilin-derived peptide, formula C35H55N11O9, mass 773.9, CAS 1801959-12-5. It was designed by shortening spadin to the residues needed to block the TREK-1 potassium channel, and it is studied in electrophysiology and rodent models as a TREK-1 inhibitor. The material here is for in-vitro research only.
What is the structure of PE-22-28?
Seven residues of the spadin sequence, retaining the channel-binding region and discarding the rest; spadin itself is seventeen residues and PubChem CID 91826106. PE-22-28 has free termini and no modifications, two basic residues and a net positive charge at neutral pH. Its mass of 773.9 is confirmed by the certificate.
| Identifier | Value |
|---|---|
| Molecular formula | C35H55N11O9 |
| Molecular weight | 773.9 g/mol |
| Residues | 7 |
| CAS number | 1801959-12-5 |
| PubChem CID | 165437303 |
| Current lot | PE2228-0528 |
How is PE-22-28 thought to work?
Spadin, released from the sortilin propeptide, blocks the two-pore-domain potassium channel TREK-1; Mazella and colleagues proposed this in 2010 as a new mechanism for modulating neuronal excitability. The shortened analogues reported by Djillani and colleagues in 2017 retained TREK-1 inhibition in patch-clamp assays with improved stability. The effect is a direct channel block measurable in cells expressing TREK-1.
Which research areas use PE-22-28?
| Area | Typical models and endpoints |
|---|---|
| TREK-1 electrophysiology | Patch-clamp current measurements in cells expressing the channel. |
| Channel selectivity | Comparisons against TREK-2, TRAAK and other K2P channels. |
| Neuronal excitability | Hippocampal slice and cultured-neuron assays. |
| Peptide design | Fragment-length versus activity and stability series derived from spadin. |
What does the published literature show?
Mazella et al. (PLoS Biology, 2010) identified spadin and its TREK-1 target in mice. Djillani et al. (Frontiers in Pharmacology, 2017) described the shortened analogues, including the 22-28 fragment, in cell and rodent work. There is no clinical programme and no human data for PE-22-28; research use is in-vitro and preclinical.
How is PE-22-28 handled in the laboratory?
Dissolves in water. No methionine or cysteine; a tyrosine gives a modest A280 signal for quantitation. Store lyophilized at minus 20 °C, aliquot solutions, freeze, and use low-binding tubes for nanomolar work, since basic peptides adsorb to plastic. The concentration table covers volumes and syringe units; the storage guide covers stability by compound class.
What does the current certificate show?
Lot PE2228-0528 tested at 99.9% purity by RP-HPLC (214 nm), identity confirmed by MALDI-MS, endotoxin <0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 10 mg per vial at $70, for laboratory research only.
Certificate history for PE-22-28
Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.
| Lot | Issued | Size | Identity | Purity | Content | Status |
|---|---|---|---|---|---|---|
| PE2228-0528 | Jun 17, 2026 | 10 mg | MALDI-MS | 99.9% | 10.21 mg | Current |
Frequently asked questions
What is spadin?
A seventeen-residue peptide derived from the propeptide of sortilin, identified in 2010 as a blocker of the TREK-1 potassium channel. PE-22-28 is the seven-residue fragment that retains that activity.
What does the current certificate show?
Lot PE2228-0528: identity by MALDI-MS at 773.9, purity 99.9% by RP-HPLC at 214 nm, content 10.21 mg, endotoxin below 0.05 EU/mL, sterility not detected. Issued 17 June 2026.
Is TREK-1 the only target?
It is the characterised one. Selectivity across the K2P family was examined in the design papers; the fragment is used as a TREK-1 tool compound.
References
- Mazella J, Pétrault O, Lucas G, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010;8(4):e1000355.
- Djillani A, Pietri M, Moreno S, et al. Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Front Pharmacol. 2017;8:643.
- PubChem CID 165437303, PE-22-28. National Library of Medicine. Read 2 October 2026.
Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.
PE-22-28 10 mg
$70 per vial
Lot PE2228-0528 · 99.9% RP-HPLC (214 nm) · certificate published
View productRelated
- P-21 research guide · P-21 5 mg
- DSIP research guide · DSIP 5 mg
- P-21: the CNTF-derived peptide, what its certificate reports, and why the same lot was certified twice
- PE-22-28: the spadin fragment, the TREK-1 channel, and what a 10 mg certificate shows
- How research peptides are made: solid-phase synthesis and where the impurities come from
- How to read a research peptide vial label
- Glossary of certificate terms
